We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Advanced Melanoma

Journal Scan / Research · March 29, 2021

TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma

Annals of Surgical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Surgical Oncology
A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis
Ann. Surg. Oncol 2021 Feb 27;[EPub Ahead of Print], TJ Vreeland, GT Clifton, DF Hale, RC Chick, AT Hickerson, JL Cindass, AM Adams, PMK Bohan, RHI Andtbacka, AC Berger, JW Jakub, JJ Sussman, AM Terando, T Wagner, GE Peoples, MB Faries

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading